Septerna (NASDAQ:SEPN) Stock Price Up 10.3% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN)’s share price shot up 10.3% during trading on Tuesday . The company traded as high as $36.98 and last traded at $36.9040. 134,133 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 338,672 shares. The stock had previously closed at $33.47.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SEPN shares. JPMorgan Chase & Co. boosted their target price on Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Truist Financial boosted their target price on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Raymond James Financial increased their target price on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. Stifel Nicolaus assumed coverage on shares of Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Septerna in a research report on Wednesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Septerna presently has an average rating of “Moderate Buy” and an average target price of $45.89.

Septerna Stock Up 9.1%

The stock has a market capitalization of $1.65 billion, a PE ratio of -45.14 and a beta of 2.29. The business’s fifty day moving average is $30.23 and its 200-day moving average is $27.71.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.23. The company had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, sell-side analysts anticipate that Septerna, Inc. will post -1.59 EPS for the current fiscal year.

Insider Buying and Selling

In other Septerna news, SVP Daniel D. Long sold 15,000 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the completion of the transaction, the senior vice president owned 96,412 shares in the company, valued at approximately $3,423,590.12. The trade was a 13.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at $4,240,247.06. This trade represents a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 48,494 shares of company stock valued at $1,566,751 in the last three months. 5.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Septerna

Several large investors have recently made changes to their positions in SEPN. Woodline Partners LP increased its holdings in Septerna by 94.2% in the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after purchasing an additional 282,585 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after buying an additional 3,323 shares during the period. Geode Capital Management LLC lifted its stake in Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after acquiring an additional 78,316 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares during the period. Finally, CW Advisors LLC acquired a new position in Septerna in the 2nd quarter valued at about $133,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.